福森藥業(01652.HK):雙黃連口服液抑制新冠病毒功效有待進一步臨牀試驗確認 集團未就有關功效作出任何聲明及保證
格隆匯2月3日丨福森藥業(01652.HK)公佈,近期有媒體報導,集團主要產品之一雙黃連口服液具有可抑制新型冠狀病毒的功效。
據悉,"雙黃連"為一種中藥配方,主要由三種草藥提取物組成,包括金銀花、黃芩及連翹,主要用於治療各種感染。
根據國家食品藥品監督管理總局備案,截至公告日期,中國已有12家制藥公司獲得生產雙黃連口服液的相關許可。
根據相關新聞文章,中國科學院上海藥物研究所及中國科學院武漢病毒研究所聯合開展的初步研究聲稱雙黃連口服液具有用於抑制新型冠狀病毒的可能性。
然而,中國科學院上海藥物研究所指出,雙黃連口服液抑制新型冠狀病毒的功效有待通過進一步臨牀試驗確認。
截至公告日期,集團尚未就雙黃連口服液抑制新型冠狀病毒的功效開展任何研究活動,亦未就有關功效作出任何聲明及保證。
公告稱,公司將密切監察新型冠狀病毒及雙黃連口服液市場需求的發展,並在必要時審視及調整雙黃連口服液的產能,以滿足市場需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.